NCAM1 and neoplasm: Two tumours that relapsed were associated with elevated NCAM levels and a residual NCAM+ALDH+ fraction and were completely eradicated by an additional course of lorvotuzumab-mertansine suggesting the NCAM+ cells were indeed responsible for tumour recurrence.